SSc patients are at a substantially increased risk of VTE and so increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted. PubMed, Arthritis Care & Research, 07/28/2015. (Also see Antiphospholipid Syndrome)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.